Prognostic DNA Methylation Biomarkers in High-risk Non–muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation

Pratik M.S. Gurung; Abigail R. Barnett; Jayne S. Wilson; John Hudson; Douglas G. Ward; Edward M. Messing; Richard T. Bryan

doi:10.1016/j.euf.2019.02.012

Prognostic DNA Methylation Biomarkers in High-risk Non–muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation

Pratik M.S. Gurung, Abigail R. Barnett, Jayne S. Wilson, John Hudson, Douglas G. Ward, Edward M. Messing, Richard T. Bryan^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

3 Citations (Scopus)

Abstract

High-risk non–muscle-invasive bladder cancers are heterogeneous in biomolecular characteristics and treatment options. Alterations in DNA methylation are commonplace in bladder cancer, and this systematic review highlights those genes in which methylation changes show promise for prognostication. These loci (CDH13, PCDHs, RUNX3, HOXA9, ISL1, and PAX6) should be validated in future prospective studies in order to translate benefit to patients.

Original language	English
Pages (from-to)	683-697
Number of pages	15
Journal	European Urology Focus
Volume	6
Issue number	4
DOIs	https://doi.org/10.1016/j.euf.2019.02.012
Publication status	Published - 15 Jul 2020

Bibliographical note

Funding Information:
Other: None. Financial disclosures: Richard T. Bryan certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: R.T. Bryan has contributed to advisory boards for Olympus Medical Systems with regard to narrow band imaging cystoscopy. Funding/Support and role of the sponsor: This study was funded by the University of Birmingham , UK.

Publisher Copyright:
© 2019 European Association of Urology

Keywords

Biomarkers
DNA
High-risk non–muscle-invasive bladder cancer
Methylation
molecular markers
Prognostic markers
Systematic review

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.euf.2019.02.012

Cite this

@article{efd60e13c62d4aecb20fa9080c52fe03,

title = "Prognostic DNA Methylation Biomarkers in High-risk Non–muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation",

abstract = "High-risk non–muscle-invasive bladder cancers are heterogeneous in biomolecular characteristics and treatment options. Alterations in DNA methylation are commonplace in bladder cancer, and this systematic review highlights those genes in which methylation changes show promise for prognostication. These loci (CDH13, PCDHs, RUNX3, HOXA9, ISL1, and PAX6) should be validated in future prospective studies in order to translate benefit to patients.",

keywords = "Biomarkers, DNA, High-risk non–muscle-invasive bladder cancer, Methylation, molecular markers, Prognostic markers, Systematic review",

author = "Gurung, {Pratik M.S.} and Barnett, {Abigail R.} and Wilson, {Jayne S.} and John Hudson and Ward, {Douglas G.} and Messing, {Edward M.} and Bryan, {Richard T.}",

note = "Funding Information: Other: None. Financial disclosures: Richard T. Bryan certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: R.T. Bryan has contributed to advisory boards for Olympus Medical Systems with regard to narrow band imaging cystoscopy. Funding/Support and role of the sponsor: This study was funded by the University of Birmingham , UK. Publisher Copyright: {\textcopyright} 2019 European Association of Urology",

year = "2020",

month = jul,

day = "15",

doi = "10.1016/j.euf.2019.02.012",

language = "English",

volume = "6",

pages = "683--697",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier",

number = "4",

}

TY - JOUR

T1 - Prognostic DNA Methylation Biomarkers in High-risk Non–muscle-invasive Bladder Cancer

T2 - A Systematic Review to Identify Loci for Prospective Validation

AU - Gurung, Pratik M.S.

AU - Barnett, Abigail R.

AU - Wilson, Jayne S.

AU - Hudson, John

AU - Ward, Douglas G.

AU - Messing, Edward M.

AU - Bryan, Richard T.

N1 - Funding Information: Other: None. Financial disclosures: Richard T. Bryan certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: R.T. Bryan has contributed to advisory boards for Olympus Medical Systems with regard to narrow band imaging cystoscopy. Funding/Support and role of the sponsor: This study was funded by the University of Birmingham , UK. Publisher Copyright: © 2019 European Association of Urology

PY - 2020/7/15

Y1 - 2020/7/15

N2 - High-risk non–muscle-invasive bladder cancers are heterogeneous in biomolecular characteristics and treatment options. Alterations in DNA methylation are commonplace in bladder cancer, and this systematic review highlights those genes in which methylation changes show promise for prognostication. These loci (CDH13, PCDHs, RUNX3, HOXA9, ISL1, and PAX6) should be validated in future prospective studies in order to translate benefit to patients.

AB - High-risk non–muscle-invasive bladder cancers are heterogeneous in biomolecular characteristics and treatment options. Alterations in DNA methylation are commonplace in bladder cancer, and this systematic review highlights those genes in which methylation changes show promise for prognostication. These loci (CDH13, PCDHs, RUNX3, HOXA9, ISL1, and PAX6) should be validated in future prospective studies in order to translate benefit to patients.

KW - Biomarkers

KW - DNA

KW - High-risk non–muscle-invasive bladder cancer

KW - Methylation

KW - molecular markers

KW - Prognostic markers

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85061818638&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.02.012

DO - 10.1016/j.euf.2019.02.012

M3 - Review article

C2 - 30803927

AN - SCOPUS:85061818638

SN - 2405-4569

VL - 6

SP - 683

EP - 697

JO - European Urology Focus

JF - European Urology Focus

IS - 4

ER -

Prognostic DNA Methylation Biomarkers in High-risk Non–muscle-invasive Bladder Cancer: A Systematic Review to Identify Loci for Prospective Validation

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this